Alpha Pro Tech APT
- Market cap
- $56.7M
- PE
- 13.6×
- 10y median 14.8×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.9×
- EV/EBIT
- 8.2×
- Revenue, 12 months
- $61.9M
- +6% on a year ago
- Net margin
- 6.8%
- Free cash flow yield
- 10.3%
Alpha Pro Tech trades at 13.6× trailing earnings, cheaper than 66% of the last ten years. Revenue was $61.9M over the last twelve months, up 6% on a year earlier with a 7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $16.1M+9% | $15.3M+25% | $13.5M−2% | $16.3M+1% | $14.3M−11% | $13.8M−10% | $13.8M+3% | $16.7M+2% | $14.8M+4% | $13.9M+0% | $14.6M+6% | $18.7M+12% | |
| Cost of revenue | $10M+1% | $9.6M+29% | $8.1M−9% | $9.4M−6% | $8.8M−13% | $8.6M−10% | $8.4M+5% | $10.5M+12% | $8.9M+2% | $8.7M+1% | $9.1M+8% | $11.7M+11% |
| Gross profit | $6M+25% | $5.7M+19% | $5.4M+9% | $6.8M+12% | $5.5M−9% | $5.2M−9% | $5.4M−1% | $6.1M−10% | $5.9M+7% | $5.1M−1% | $5.5M+2% | $7M+14% |
| SG&A | $4.4M+11% | $4.5M+16% | $4.8M+12% | $4.9M+7% | $4.5M+3% | $4.4M−3% | $4.7M−3% | $4.6M−7% | $4.6M+2% | $4M−10% | $4.7M−0% | $4.7M+3% |
| $1.4M+120% | $971K+28% | $326K−24% | $1.7M+31% | $737K−48% | $674K−31% | $455K+40% | $1.3M−22% | $1.1M+49% | $952K+41% | $580K+28% | $2M+51% | |
| Pre-tax income | $1.8M+176% | $1.3M+52% | $722K+4% | $2.1M+34% | $1.1M−40% | $1.1M−18% | $772K+7% | $1.6M−24% | $1.3M+18% | $993K−8% | $885K+15% | $2.4M+48% |
| $395K+148% | $262K−14% | $146K+4% | $475K+8% | $237K−40% | $233K−11% | $159K+9% | $367K−23% | $317K+34% | $295K+27% | $183K+15% | $558K+52% | |
| Net income | $1.4M+184% | $1.1M+88% | $576K+4% | $1.6M+44% | $862K−40% | $847K−20% | $613K+6% | $1.2M−24% | $976K+13% | $698K−18% | $702K+15% | $1.8M+47% |
| $0.12+200% | $0.09+80% | $0.05+0% | $0.15+50% | $0.08−33% | $0.07−22% | $0.06+20% | $0.12−20% | $0.09+13% | $0.07+0% | $0.07+17% | $0.18+50% | |
| 11.8M−7% | 11.5M−7% | 11.4M−7% | 11.2M−7% | 11.2M−5% | 11.4M−1% | 10.8M−5% | 10.6M−6% | 10.5M−6% | 10.3M−10% | 10.3M−5% | 10.3M−3% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Alpha Pro Tech's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| Peer median | $236.3M | 21.9× | 20.9× | 1.9× | +5% | 8.4% |
More on Alpha Pro Tech
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 45Medical instruments and supplies stocks with the highest free cash flow yield
- #5of 46Medical instruments and supplies stocks with the lowest EV/EBIT
- #4of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .